SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Scientists from Trellis Bioscience are presenting data today on their discovery of monoclonal antibodies from human blood against a target protein of the respiratory syncytial virus (RSV). The antibodies were identified and isolated directly from the antibody producing B cells of RSV-infected patients, using a proprietary process called CellspotTM developed at Trellis. These human anti-RSV antibodies are being evaluated for therapeutic utility in animal models of RSV infection. Findings are being presented at the RSV 2007 Symposium held at Marco Island, Florida.
